SAVIMS

SAVIMS logo white
Menu

Vaccine risk benefit analysis

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Evaluating the Life-Saving Claims of the COVID-19 Vaccine

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Rancourt, D.G., & Hickey, J. (2023). Quantitative evaluation of whether the Nobel-Prize-winning COVID-19 vaccine actually saved millions of lives. CORRELATION Research in the Public Interest, Brief Report. https://correlation-canada.org/nobel-vaccine-and-all-cause-mortality/ Summary: In their report, Rancourt and Hickey critically assess claims that Nobel-Prize-winning COVID-19 vaccines saved millions of lives, primarily based on theoretical models by Watson et […]

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

PfizerGate: The Alarming Correlation Between COVID Vaccines and Excess Deaths

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: The Exposé. (2022, December 26). PfizerGate: Tragic truth behind COVID vaccines: 50k Brits have died suddenly in 8 months due to vaccination causing a 5-month countdown to death. https://expose-news.com/2022/12/26/pfizergate-50k-brits-died-suddenly-covid-vaccination Summary: The article by The Exposé raises alarming concerns regarding an unprecedented rise in deaths in Britain since the introduction of COVID-19 vaccines. Official statistics

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Natural Infection vs. mRNA Vaccination in COVID-19: Insights from Qatar

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Reference: Chemaitelly, H., AlMukdad, S., Butt, A. A., Abu-Raddad, L. J., Ayoub, H. H., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Khal, A., Al-Thani, M.

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Periodic Safety Update Report on COVID-19 mRNA Vaccine (BNT162b2)

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: BioNTech Manufacturing GmbH. (2022). COVID-19 mRNA vaccine (nucleoside modified) Reporting Period Periodic Safety Update Report (PSUR) 3: 19 December 2021 through 18 June 2022. Summary: The third Periodic Safety Update Report (PSUR) for the COVID-19 mRNA vaccine (BNT162b2), also known as COMIRNATY®, covers data from 19 December 2021 to 18 June 2022. It outlines

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccines, Viral illnesses

COVID Vaccination and Mortality Risk: A Critical Analysis

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Reference: Pantazatos, S. P., & Seligmann, H. (2021). COVID vaccination and age-stratified all-cause mortality risk. Preprint. https://doi.org/10.13140/RG.2.2.28257.43366 Summary: This article examines the relationship between COVID-19 vaccination and all-cause mortality risk across different age groups. Using publicly available data from the US and Europe, the authors conducted analyses to determine whether vaccination rates correlate with subsequent

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Anomalies in UK Vaccine Mortality Data

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Neil, M., Fenton, N., Smalley, J., Craig, C. E. H., Guetzkow, J., McLachlan, S., Engler, J., Russell, D., & Rose, J. (2022). Official mortality data for England suggest systematic miscategorisation of vaccine status and uncertain effectiveness of Covid-19 vaccination. Preprint. https://doi.org/10.13140/RG.2.2.28055.09124 Summary: The article critiques UK official mortality data regarding Covid-19 vaccination effectiveness, highlighting

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Understanding RRR and ARR in Vaccine Trials

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Reference: Iriarte, I., & Phoenix, S. (2021). Understanding relative risk reduction (RRR) and absolute risk reduction (ARR) in vaccine trials. PANDA. https://www.pandata.org/understanding-relative-risk-reduction-and-absolute-risk-reduction-in-vaccine-trials/ Summary: The article discusses the critical distinctions between Relative Risk Reduction (RRR) and Absolute Risk Reduction (ARR) in the context of vaccine trials, particularly those for COVID-19. RRR compares the efficacy of one

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Annual Renewal of Conditional Marketing Authorisation for Comirnaty

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: European Medicines Agency. (2021). Assessment report on the annual renewal of the conditional marketing authorisation. EMA/596333/2021. Summary: The European Medicines Agency (EMA) assessed the annual renewal of the conditional marketing authorisation for Comirnaty, a COVID-19 mRNA vaccine developed by BioNTech. Initially granted on 21 December 2020, the renewal process involved reviewing specific obligations (SOBs)

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

US COVID-19 Vaccines: A Critical Analysis of Health Impact

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Classen, B. (2021). US COVID-19 vaccines proven to cause more harm than good based on pivotal clinical trial data analysed using the proper scientific endpoint, “all cause severe morbidity”. Trends in Internal Medicine, 1(1), 1-6. Summary: The article by J. Bart Classen critiques the three COVID-19 vaccines approved in the US, asserting that they

Scroll to Top